Clarity’s PROPELLER Results Win Top Prize at prestigious nuclear medicine conference
Sydney, Australia 17 July 2023 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”, “the Company”), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, has been awarded First Place in the Oncology, Clinical Therapy & Diagnosis category at the world’s most prestigious nuclear medicine conference,…